BIOMAT Database Logo BIOMAT Database Logo

Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. 2000

E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018445 Infectious Disease Transmission, Vertical The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding. Fetomaternal Infection Transmission,Infection Transmission, Fetomaternal,Infection Transmission, Maternal-Fetal,Infection Transmission, Vertical,Maternal-Fetal Infection Transmission,Mother-to-Child Transmission,Pathogen Transmission, Vertical,Vertical Infection Transmission,Vertical Infectious Disease Transmission,Vertical Transmission of Infectious Disease,Infection Transmission, Maternal Fetal,Maternal Fetal Infection Transmission,Mother to Child Transmission,Mother-to-Child Transmissions,Transmission, Fetomaternal Infection,Transmission, Maternal-Fetal Infection,Transmission, Mother-to-Child,Transmission, Vertical Infection,Transmission, Vertical Pathogen,Transmissions, Mother-to-Child,Vertical Pathogen Transmission

Related Publications

E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women.
November 1999, Obstetrics and gynecology,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Persistent Immune Activation in Human Immunodeficiency Virus-Infected Pregnant Women Starting Combination Antiretroviral Therapy After Conception.
April 2022, The Journal of infectious diseases,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Human Immunodeficiency Virus Viral Load Rebound Near Delivery in Previously Suppressed, Combination Antiretroviral Therapy-Treated Pregnant Women.
September 2017, Obstetrics and gynecology,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Combination antiretroviral therapy in 100 HIV-1-infected pregnant women.
February 2002, Human reproduction (Oxford, England),
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Antiretroviral therapy in human immunodeficiency virus-infected individuals.
January 1998, Advances in internal medicine,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis.
February 2000, Obstetrics and gynecology,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Immunosuppression in pregnant women infected with human immunodeficiency virus.
November 1989, American journal of obstetrics and gynecology,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Care of pregnant women infected with human immunodeficiency virus.
November 1987, JAMA,
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
January 1999, AIDS (London, England),
E Visconti, and L P Celentano, and E Tamburrini, and P Villa, and G Oliva, and C Fundaro
Risk of Preeclampsia in Human Immunodeficiency Virus-Infected Pregnant Women.
June 2016, Obstetrics and gynecology,
Copied contents to your clipboard!